CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 202231Orig1s000

MEDICAL REVIEW(S)



CLINICAL REVIEW

Application Type NDA
Application Number(s) 202,231
Priority or Standard Standard

Submit Date(s) August 30, 2010 Received Date(s) August 31, 2010 PDUFA Goal Date June 30, 2011 Division / Office DMEP/OND II

Reviewer Name(s) Naomi Lowy, MD Review Completion Date May 11, 2011

Established Name Levothyroxine sodium for

injection

(Proposed) Trade Name Levothyroxine sodium for

injection

Therapeutic Class Thyroid hormone

Applicant APP Pharmaceuticals, LLC

Formulation(s) Injection

Dosing Regimen Initial loading dose of 300-500

µg IV followed by daily

maintenance doses of 50-100

mcg until oral therapy is

tolerated

Indication(s) Treatment of myxedema coma

Intended Population(s) Adults



Template Version: March 6, 2009

APPEARS THIS WAY ON ORIGINAL



Table of Contents

1	RE	COMMENDATIONS/RISK BENEFIT ASSESSMENT	7	
	1.1 1.2 1.3 1.4	Recommendation on Regulatory Action	g	
2	INT	RODUCTION AND REGULATORY BACKGROUND	9	
	2.1 2.2 2.3 2.4 2.5 2.6	Product Information	9 9 10	
3	ETI	HICS AND GOOD CLINICAL PRACTICES	10	
	3.1 3.2 3.3	Submission Quality and Integrity Compliance with Good Clinical Practices Financial Disclosures	11	
4	4 SIGNIFICANT EFFICACY/SAFETY ISSUES RELATED TO OTHER REVIEW DISCIPLINES			
	4.1 4.2 4.3 4.4 4.4 4.4		11 12 12 12	
5	SO	URCES OF CLINICAL DATA	12	
	5.1 5.2 5.3	Tables of Studies/Clinical Trials	12	
6	RE'	VIEW OF EFFICACY	13	
	Effica 6.1 6.1 6.1	1.1 Methods	14 15	
7		VIEW OF SAFETY		
	Safet	ty Summary	24	



	7.1 Me	ethods	24
		equacy of Safety Assessments	
		Overall Exposure at Appropriate Doses/Durations and Demographics of	
		Target Populations	26
	7.3 Ma	ajor Safety Results	
	7.3.1	Deaths	
	7.3.4	Significant Adverse Events	
	7.4 Su	pportive Safety Results	. 32
	7.5.1	Dose Dependency for Adverse Events	. 32
	7.5.2		
	7.5.4	Drug-Disease Interactions	. 33
	7.5.5	Drug-Drug Interactions	. 33
	7.6 Ad	ditional Safety Evaluations	33
	7.6.1	Human Carcinogenicity	. 33
	7.6.2	Human Reproduction and Pregnancy Data	. 33
	7.6.3	Pediatrics and Assessment of Effects on Growth	. 33
	7.6.4	Overdose, Drug Abuse Potential, Withdrawal and Rebound	. 34
8	POSTI	MARKET EXPERIENCE	. 34
9	APPE	NDICES	35
	9.1 Lite	erature Review/References	35
		beling Recommendations	
		visory Committee Meeting	. 54



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

